PHASE 1 CELL DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF GENETICALLY ENGINEERED MAGE-A10 C796T IN HLA-A2+ SUBJECTS WITH MAGE-A10 POSITIVE UROTHELIAL, MELANOMA OR HEAD AND NECK TUMORS

T cells are a type of white blood cell that work as a part of your immune system. In this study, your own T cells will be collected and genetically changed to make the MAGE-A10 study drug. The study drug is designed to use your genetically changed T cells to specifically target and attack cancer cells. The goal of this clinical research study is to find the highest tolerable dose of the study drug that can be safely given to cancer patients. Researchers also want to learn about possible side effects of the study drug and if the study drug can help to control the disease.

Disease Group: Malignant neoplasms of ill-defined secondary and unspecified sites,Malignant neoplasms of urinary tract,Melanoma and other malignant neoplasms of skin

Treatment Agent: Cyclophosphamide,Fludarabine,MAGE-A10c796T,MESNA,Neupogen

Treatment Location: Both at MDACC & and Other Sites

Sponsor: STRATEGIC ALLIANCE: Adaptimmune, LLC

IRB Review and Approval Date: 12/09/2016

Recruitment Status: Open

Projected Accrual: 19

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT02989064